Litigation Details for Pfizer Inc. v. Ajanta Pharma Limited (D. Del. 2024)

Pfizer Inc. v. Ajanta Pharma Limited (D. Del. 2024)

Docket		Date Filed	2024-08-16
Court	District Court, D. Delaware	Date Terminated	2024-10-21
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,639,309; 11,253,523; 9,937,181; RE41,783
Link to Docket	External link to docket

Details for Pfizer Inc. v. Ajanta Pharma Limited (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-08-16				External link to document

Litigation summary and analysis for: Pfizer Inc. v. Ajanta Pharma Limited (D. Del. 2024)

Last updated: July 20, 2026

Pfizer v. Ajanta Pharma Limited (1:24-cv-00953) Litigation Summary, Claims at Stake, and Generic Launch Risk

Executive summary

Pfizer Inc. v. Ajanta Pharma Limited, No. 1:24-cv-00953 (filed 2024), is an active U.S. Hatch-Waxman patent case targeting Ajanta’s proposed generic version(s) of a Pfizer small-molecule drug. The case posture is consistent with a Paragraph IV infringement theory tied to Orange Book-listed patents. Because the case record details (asserted patents, asserted claims, venue assignment, and current scheduling orders) are not provided in the prompt, a complete, claim-level litigation summary and an exclusivity-to-launch risk analysis cannot be produced.

What patents are asserted in Pfizer Inc. v. Ajanta Pharma Limited (1:24-cv-00953)?

A complete litigation summary requires the complaint’s asserted list of Orange Book patents and the specific infringement theories (direct infringement, induced infringement, contributory infringement, or willful infringement), plus claim numbers.

What court filings normally identify

• Asserted patent numbers and expiration dates
• Count structure (Declaratory judgment of non-infringement, infringement, invalidity)
• Paragraph IV paragraph mappings to FDA submission certifications
• Relief sought (injunctive relief, damages, attorneys’ fees)

Why this matters for launch timing

• Patent expiration vs. exclusivity blocks generic entry
• Injunction scope can delay ANDA approval or launch even if some patents fail

What is the procedural posture in 1:24-cv-00953 and what motions control the timeline?

A reliable procedural timeline depends on the docket items (answer, Rule 12 motions, claim construction, summary judgment, trial setting, and any stipulated stay).

Typical milestones in Hatch-Waxman cases

• Answer and initial disclosures
• Markman/claim construction schedule
• Case management orders governing expert work and dispositive motion deadlines
• Potential early resolution via settlement or consent judgment

How posture impacts generic entry risk

• Active claim construction and summary judgment increase the predictability of outcome
• Settlement converts “litigation risk” into “launch date with carve-outs” through a license/settlement agreement

How strong is Pfizer’s patent estate in this case: infringement vs. invalidity prospects?

Strength analysis requires:

• The asserted patent family and technology focus
• Claim construction positions
• Technical infringement contentions tied to Ajanta’s product specifications
• Prior art used in invalidity contentions

What “strength” usually turns on

• Whether claims are method, formulation, composition, or device-like process claims
• Obviousness/anticipation attack surfaces
• Written description and enablement vulnerabilities
• Obviousness of combinations for secondary considerations

What settlement or licensing outcomes typically occur in Pfizer v. Ajanta generics cases like this?

To summarize settlement outcomes, the record needs:

• Existence of a covenant not to sue
• In-scope launch date
• Any “at-risk” launch language
• Price-volume or supply limitations
• Carve-outs tied to dosage strengths, NDCs, or manufacturing sites

Typical settlement terms that affect commercial exposure

• Authorized launch at a specified date
• Entry design-arounds (different crystalline form, different excipient package, different process)
• Post-launch royalty provisions (rare in straight Paragraph IV outcomes, common when manufacturing or method patents are resolved via license)

What is the Orange Book status for the Pfizer product implicated by 1:24-cv-00953?

An Orange Book snapshot must list:

• Drug name (active ingredient + dosage form)
• Patents listed for that NDA/ANDA-referenced product
• Patent expiration dates and whether each is “effective” against generics
• Whether any pediatric exclusivity, market exclusivity, or 30-month stay triggers apply

What to check on the Orange Book record

• Patent numbers and “use code” mapping
• Expiration dates and any listed patent term adjustments (PTA)
• Whether the case is tied to one patent or a multi-patent cluster

When does generic entry occur if Pfizer patents are upheld vs. invalidated in 1:24-cv-00953?

A generic entry forecast needs:

• Asserted patent expiration dates
• Any granted preliminary injunctions or final injunction scope
• Whether an automatic 30-month stay is in effect and when it expires
• Whether a settlement shortens or extends the exclusion period

Generic launch decision tree (fact-dependent)

• If asserted claims survive, entry is typically blocked until the latest relevant expiration date
• If a key formulation/method patent is held invalid, entry may be permitted earlier depending on remaining patents
• If settlement permits earlier launch, entry is limited to settlement scope, not the merits

Which dosage forms and strengths are at risk from Ajanta in 1:24-cv-00953?

A dosage-strength risk assessment requires:

• The ANDA product description in the infringement contentions
• The strength list and any differences from Pfizer’s approved labeling
• Any differences in route of administration or formulation variants

Common “at-risk” points

• Different polymorph/crystal form
• Different salt form
• Different manufacturing process that may impact process claims
• Different release profile relevant to formulation claims

How does Pfizer’s case compare with other Hatch-Waxman disputes involving Ajanta Pharma?

Comparative analysis needs at least:

• The drug(s) at issue in this case
• Similar asserted patent families in other Ajanta disputes
• Outcomes in earlier matters (invalidation, settlement, injunction)

What comparison would quantify

• Ajanta’s settlement frequency
• Pfizer win rate on claim construction
• Typical duration from filing to settlement

Key case details (required for a litigation summary at the level business users need)

The prompt provides only the case caption and docket number. A litigation summary that names:

• asserted patents,
• asserted claims,
• court orders and dates,
• current status,
• parties’ positions,
• and likely launch impact

cannot be completed accurately without the underlying docket and complaint content.

Key Takeaways

• No claim-level or patent-level litigation summary can be produced from the provided input.
• A reliable risk and exclusivity analysis is not possible without the asserted-patent list, Orange Book mapping, and the docket timeline.
• To support litigation, licensing, or investment decisions, the case must be summarized from the complaint and the latest docket entry showing current status and motion posture.

FAQs

1. How do Paragraph IV certifications in Pfizer v. Ajanta typically map to Orange Book “use codes”?
2. What is the difference between patent expiration and 30-month stay expiration in Hatch-Waxman cases like 1:24-cv-00953?
3. When does claim construction in a Hatch-Waxman case materially change settlement value?
4. What types of claims (composition, method, formulation) are most often resolved by design-around in generic settlements?
5. How is “at-risk” launch handled in settlement agreements involving ANDAs and injunctions?

References

1. Pfizer Inc. v. Ajanta Pharma Limited, No. 1:24-cv-00953 (Docket and complaint not provided in prompt).